Are SGLT2 Inhibitors Ready for Prime Time for CKD?
作者信息
Pecoits-Filho Roberto, Perkovic Vlado
机构信息
George Institute for Global Health, Newtown, New South Wales, Australia.
School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil; and.
出版信息
Clin J Am Soc Nephrol. 2018 Feb 7;13(2):318-320. doi: 10.2215/CJN.07680717. Epub 2017 Sep 11.
Abstract
摘要
相似文献
1
Are SGLT2 Inhibitors Ready for Prime Time for CKD?钠-葡萄糖协同转运蛋白2抑制剂对慢性肾脏病而言已准备好进入黄金时期了吗？
Clin J Am Soc Nephrol. 2018 Feb 7;13(2):318-320. doi: 10.2215/CJN.07680717. Epub 2017 Sep 11.
2
Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease.钠-葡萄糖协同转运蛋白2抑制剂预示着糖尿病肾病防治行动的号角。
Clin J Am Soc Nephrol. 2020 Feb 7;15(2):285-288. doi: 10.2215/CJN.07730719. Epub 2019 Nov 18.
3
Sweet success? SGLT2 inhibitors and diabetes.甜蜜的成功？钠-葡萄糖协同转运蛋白2抑制剂与糖尿病
Am J Physiol Renal Physiol. 2018 Jun 1;314(6):F1034-F1035. doi: 10.1152/ajprenal.00557.2017. Epub 2017 Dec 27.
4
Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney.通过 SGLT-2 抑制预防 2 型糖尿病患者的主要不良心血管事件：肾脏的作用。
Cardiovasc Diabetol. 2020 Mar 19;19(1):35. doi: 10.1186/s12933-020-01010-x.
5
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.SGLT2 抑制剂的肾脏和心血管保护机制评估：基于模型的临床数据分析。
Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1295-F1306. doi: 10.1152/ajprenal.00202.2018. Epub 2018 Jul 18.
6
Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.糖尿病肾病患者的血压管理与钠-葡萄糖共转运蛋白 2 抑制剂的肾脏效应之间的关系。
J Diabetes Res. 2019 Nov 3;2019:9415313. doi: 10.1155/2019/9415313. eCollection 2019.
7
SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.SGLT2 抑制剂在糖尿病肾病防治中的应用：综述
Am J Kidney Dis. 2018 Aug;72(2):267-277. doi: 10.1053/j.ajkd.2018.03.022. Epub 2018 Jun 14.
8
Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.钠-葡萄糖协同转运蛋白2抑制剂对日本2型糖尿病合并慢性肾脏病患者疗效的回顾性分析
Diab Vasc Dis Res. 2019 Jan;16(1):103-107. doi: 10.1177/1479164118802759. Epub 2018 Oct 4.
9
Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.背景和设计：一项由研究者发起的、多中心、前瞻性、开放标签、随机试验，旨在评估伊格列净对 2 型糖尿病和慢性肾脏病患者内皮功能障碍的影响：PROCEED 试验。
Cardiovasc Diabetol. 2020 Jun 13;19(1):85. doi: 10.1186/s12933-020-01065-w.
10
Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.重点更新：心力衰竭和/或慢性肾脏病患者的 SGLT2 抑制剂。
Ann Pharmacother. 2021 Feb;55(2):252-260. doi: 10.1177/1060028020934001. Epub 2020 Jun 13.
引用本文的文献
1
Mechanistic Study of Fruit Mixture Based on Network Pharmacology, Molecular Docking and Experimental Validation to Improve the Inflammatory Response of DKD Through AGEs/RAGE Signaling Pathway.基于网络药理学、分子对接和实验验证的水果混合物作用机制研究，通过 AGEs/RAGE 信号通路改善 DKD 的炎症反应。
Drug Des Devel Ther. 2023 Feb 27;17:613-632. doi: 10.2147/DDDT.S395512. eCollection 2023.
2
Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort.英国慢性肾脏病患者的医疗资源利用情况及相关费用：来自DISCOVER CKD回顾性队列研究的报告
Clin Kidney J. 2022 Jul 26;15(11):2124-2134. doi: 10.1093/ckj/sfac168. eCollection 2022 Nov.
3
Efficacy and Safety of "Bushen Huoxue Therapy"-Based Combined Chinese and Western Medicine Treatment for Diabetic Kidney Disease: an Updated Meta-Analysis of 2105 Patients.基于“补肾活血法”的中西医结合治疗糖尿病肾病的疗效与安全性：2105例患者的最新Meta分析
Evid Based Complement Alternat Med. 2022 Jan 12;2022:3710074. doi: 10.1155/2022/3710074. eCollection 2022.
4
Deciphering the Efficacy and Mechanisms of Chinese Herbal Medicine for Diabetic Kidney Disease by Integrating Web-Based Biochemical Databases and Real-World Clinical Data: Retrospective Cohort Study.通过整合基于网络的生化数据库和真实世界临床数据解读中药治疗糖尿病肾病的疗效及机制：回顾性队列研究
JMIR Med Inform. 2021 May 11;9(5):e27614. doi: 10.2196/27614.
5
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?钠-葡萄糖共转运蛋白 2 抑制剂：未来应治疗哪些慢性肾脏病患者？
Nephrol Dial Transplant. 2020 Jan 1;35(Suppl 1):i48-i55. doi: 10.1093/ndt/gfz252.
6
Renal effects of SGLT2 inhibitors: an update.SGLT2 抑制剂的肾脏作用：更新。
Curr Opin Nephrol Hypertens. 2020 Mar;29(2):190-198. doi: 10.1097/MNH.0000000000000584.
7
How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.有多少 2 型糖尿病患者符合 SGLT2 抑制剂心血管结局试验的纳入标准？来自地中海地区人群数据库的估计。
J Diabetes Res. 2019 Nov 11;2019:2018374. doi: 10.1155/2019/2018374. eCollection 2019.
8
The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.达格列净对伴有或不伴有肾素-血管紧张素系统抑制剂治疗的 2 型糖尿病患者心肾风险因素的影响：一项事后分析。
Diabetes Obes Metab. 2020 Apr;22(4):549-556. doi: 10.1111/dom.13923. Epub 2019 Dec 14.
9
Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats.恩格列净对去单侧肾大鼠非糖尿病盐敏感性高血压的影响。
Hypertens Res. 2019 Dec;42(12):1905-1915. doi: 10.1038/s41440-019-0326-3. Epub 2019 Sep 19.
10
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.卡格列净对不同白蛋白尿水平的肾脏和心血管结局的影响：来自 CANVAS 项目的数据。
J Am Soc Nephrol. 2019 Nov;30(11):2229-2242. doi: 10.1681/ASN.2019010064. Epub 2019 Sep 17.
Zotero 插件